72420-38-3
72420-38-3
Chemical Structure
Acifran
Synonym(s): AY 25712
- CAS No.: 72420-38-3
- Formula:C12H10O4
- Molecular Weight:218.21
IUPAC Name: 5-methyl-4-oxo-5-phenyl-4,5-dihydrofuran-2-carboxylic acid
InChIKey: DFDGRKNOFOJBAJ-UHFFFAOYSA-N
SMILES: O=C(C(OC1(C)C2=CC=CC=C2)=CC1=O)O
Biological Activity: Acifran (AY 25712) is an orally active, full GPR109A and GPR109B agonist and hypolipidemic agent. Acifran reduces Forskolin (HY-15371)-induced cAMP elevation, triggers ERK1/ERK2 phosphorylation, and inhibits lipolysis in adipose tissue through Gi-coupled GPCR activation. Acifran is used for research on atherosclerosis, hyperlipidemia, and type 2 diabetes[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Acifran | 99.03% | Acifran (AY 25712) is an orally active, full GPR109A and GPR109B agonist and hypolipidemic agent. Acifran reduces Forskolin (HY-15371)-induced cAMP elevation, triggers ERK1/ERK2 phosphorylation, and inhibits lipolysis in adipose tissue through Gi-coupled GPCR activation. Acifran is used for research on atherosclerosis, hyperlipidemia, and type 2 diabetes. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Acifran (Standard) | ≥98% | Acifran (Standard) (AY 25712 (Standard)) is the analytical standard of Acifran (HY-107579). This product is intended for research and analytical applications. Acifran (AY 25712) is an orally active, full GPR109A and GPR109B agonist and hypolipidemic agent. Acifran reduces Forskolin (HY-15371)-induced cAMP elevation, triggers ERK1/ERK2 phosphorylation, and inhibits lipolysis in adipose tissue through Gi-coupled GPCR activation. Acifran is used for research on atherosclerosis, hyperlipidemia, and type 2 diabetes. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Jung JK, et al. Analogues of acifran: agonists of the high and low affinity niacin receptors, GPR109a and GPR109b. Journal of medicinal chemistry. 2007 Apr 05;50(7):1445-8. [Content Brief]
- [2]. Cayen MN, et al. The metabolic disposition of acifran, a new antihyperlipidemic agent, in rats and dogs. Xenobiotica; the fate of foreign compounds in biological systems. 1986 Mar;16(3):251-63. [Content Brief]
- [3]. Mahboubi K, et al. Triglyceride modulation by acifran analogs: activity towards the niacin high and low affinity G protein-coupled receptors HM74A and HM74. Biochemical and biophysical research communications. 2006 Feb 10;340(2):482-90.
